

# Marie-Luise Berres

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6228513/publications.pdf>

Version: 2024-02-01

52  
papers

3,263  
citations

201674

27  
h-index

206112

48  
g-index

54  
all docs

54  
docs citations

54  
times ranked

5788  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel short-termed mouse model of intrahepatic cholangiocarcinoma by orthotopic transplantation of Hep-55.1C in mice with human homology. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.5	0
2	CXCR3 is a key regulator during macrophage differentiation and has a significant impact on tumor-associated macrophages. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.5	0
3	<scp>JAM&A</scp> is a multifaceted regulator in hepatic fibrogenesis, supporting <scp>LSEC</scp> integrity and stellate cell quiescence. <i>Liver International</i> , 2022, 42, 1185-1203.	3.9	5
4	Extracellular Vesicles from Steatotic Hepatocytes Provoke Pro-Fibrotic Responses in Cultured Stellate Cells. <i>Biomolecules</i> , 2022, 12, 698.	4.0	3
5	Unexpected Pro-Fibrotic Effect of MIF in Non-Alcoholic Steatohepatitis Is Linked to a Shift in NKT Cell Populations. <i>Cells</i> , 2021, 10, 252.	4.1	11
6	Balance between macrophage migration inhibitory factor and sCD74 predicts outcome in patients with acute decompensation of cirrhosis. <i>JHEP Reports</i> , 2021, 3, 100221.	4.9	12
7	Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies. <i>Clinical and Translational Science</i> , 2021, 14, 1853-1863.	3.1	6
8	Macrophage migration inhibitory factor exerts pro&Ecirc;proliferative and anti&Ecirc;apoptotic effects via CD74 in murine hepatocellular carcinoma. <i>British Journal of Pharmacology</i> , 2021, 178, 4452-4467.	5.4	20
9	Role of circulating angiogenin levels in portal hypertension and TIPS. <i>PLoS ONE</i> , 2021, 16, e0256473.	2.5	2
10	A Radiomics Approach to Predict the Emergence of New Hepatocellular Carcinoma in Computed Tomography for High-Risk Patients with Liver Cirrhosis. <i>Diagnostics</i> , 2021, 11, 1650.	2.6	1
11	Liver Fibrosis&Ecirc;From Mechanisms of Injury to Modulation of Disease. <i>Frontiers in Medicine</i> , 2021, 8, 814496.	2.6	9
12	Systemic MCP-1 Levels Derive Mainly From Injured Liver and Are Associated With Complications in Cirrhosis. <i>Frontiers in Immunology</i> , 2020, 11, 354.	4.8	27
13	Dietary Intake Regulates the Circulating Inflammatory Monocyte Pool. <i>Cell</i> , 2019, 178, 1102-1114.e17.	28.9	254
14	Genetic Variants in the Promoter Region of the Macrophage Migration Inhibitory Factor are Associated with the Severity of Hepatitis C Virus-Induced Liver Fibrosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3753.	4.1	5
15	Liver DCs in health and disease. <i>International Review of Cell and Molecular Biology</i> , 2019, 348, 263-299.	3.2	9
16	THU-471-Establishment of a short-termed orthotopic transplantation model in C57/B6 mice that recapitulates characteristic features of human intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2019, 70, e367-e368.	3.7	0
17	Platelet Factor 4 Attenuates Experimental Acute Liver Injury in Mice. <i>Frontiers in Physiology</i> , 2019, 10, 326.	2.8	10
18	Excellent Response to Anti-PD-1 Therapy in a Patient with Hepatocellular Carcinoma Intolerant to Sorafenib. <i>Visceral Medicine</i> , 2019, 35, 43-46.	1.3	6

#	ARTICLE	IF	CITATIONS
19	Influence of Liver Fibrosis on Lobular Zonation. <i>Cells</i> , 2019, 8, 1556.	4.1	51
20	RAF/MEK/extracellular signalâ€related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. <i>Journal of Experimental Medicine</i> , 2018, 215, 319-336.	8.5	58
21	Circulating <sc>CXCL</sc>10 in cirrhotic portal hypertension might reflect systemic inflammation and predict <sc>ACLF</sc> and mortality. <i>Liver International</i> , 2018, 38, 875-884.	3.9	35
22	Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. <i>Nature Communications</i> , 2018, 9, 4962.	12.8	111
23	Chemokine (Câ€Xâ€ motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. <i>Liver International</i> , 2016, 36, 386-394.	3.9	36
24	CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt. <i>Journal of Hepatology</i> , 2015, 62, 332-339.	3.7	58
25	Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?. <i>British Journal of Haematology</i> , 2015, 169, 3-13.	2.5	141
26	Protective role of macrophage migration inhibitory factor in nonalcoholic steatohepatitis. <i>FASEB Journal</i> , 2014, 28, 5136-5147.	0.5	51
27	<i>BRAF-V600E</i> expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. <i>Journal of Experimental Medicine</i> , 2014, 211, 669-683.	8.5	346
28	Crosstalk between Muscularis Macrophages and Enteric Neurons Regulates Gastrointestinal Motility. <i>Cell</i> , 2014, 158, 300-313.	28.9	498
29	Pathological Consequence of Misguided Dendritic Cell Differentiation in Histiocytic Diseases. <i>Advances in Immunology</i> , 2013, 120, 127-161.	2.2	61
30	Proapoptotic effects of the chemokine, CXCL 10 are mediated by the noncognate receptor TLR4 in hepatocytes. <i>Hepatology</i> , 2013, 57, 797-805.	7.3	51
31	The Chemokine CCL3 Promotes Experimental Liver Fibrosis in Mice. <i>PLoS ONE</i> , 2013, 8, e66106.	2.5	58
32	Hematopoietic Stem Cells and Circulating Myelomonocytic Precursors With BRAF-V600E Are Identified In High-Risk Patients and Define LCH As a Myeloid Neoplasia. <i>Blood</i> , 2013, 122, 103-103.	1.4	0
33	Met-CCL5 modifies monocyte subpopulations during liver fibrosis regression. <i>International Journal of Clinical and Experimental Pathology</i> , 2013, 6, 678-85.	0.5	14
34	The chemokine receptor CXCR3 limits injury after acute toxic liver damage. <i>Laboratory Investigation</i> , 2012, 92, 724-734.	3.7	18
35	Soluble Urokinase Plasminogen Activator Receptor is Associated With Progressive Liver Fibrosis in Hepatitis C Infection. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 334-338.	2.2	37
36	Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice. <i>Hepatology</i> , 2012, 55, 1610-1619.	7.3	110

#	ARTICLE	IF	CITATIONS
37	Interference with Oligomerization and Glycosaminoglycan Binding of the Chemokine CCL5 Improves Experimental Liver Injury. <i>PLoS ONE</i> , 2012, 7, e36614.	2.5	15
38	Therapeutic potential of chemokine receptor antagonists for liver disease. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 503-513.	3.1	8
39	A Duffy antigen receptor for chemokines (DARC) polymorphism that determines pro-fibrotic chemokine serum concentrations is not directly associated with severity of hepatitis C infection. <i>Human Immunology</i> , 2011, 72, 273-277.	2.4	8
40	Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases. <i>Liver International</i> , 2011, 31, 840-849.	3.9	54
41	Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection. <i>Hepatology</i> , 2011, 53, 596-603.	7.3	70
42	Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 17444-17449.	7.1	133
43	CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. <i>Hepatology</i> , 2010, 51, 1345-1353.	7.3	144
44	Chemokines as Immune Mediators of Liver Diseases Related to the Metabolic Syndrome. <i>Digestive Diseases</i> , 2010, 28, 192-196.	1.9	22
45	Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. <i>Journal of Clinical Investigation</i> , 2010, 120, 4129-4140.	8.2	227
46	The chemokine scavenging receptor D6 limits acute toxic liver injury <i>in vivo</i> . <i>Biological Chemistry</i> , 2009, 390, 1039-1045.	2.5	28
47	Longitudinal monocyte Human leukocyte antigen-DR expression is a prognostic marker in critically ill patients with decompensated liver cirrhosis. <i>Liver International</i> , 2009, 29, 536-543.	3.9	63
48	A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. <i>Journal of Hepatology</i> , 2009, 50, 370-376.	3.7	75
49	Genetic variations of the chemokine scavenger receptor D6 are associated with liver inflammation in chronic hepatitis C. <i>Human Immunology</i> , 2008, 69, 861-866.	2.4	25
50	The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. <i>Journal of Hepatology</i> , 2008, 48, 208-215.	3.7	66
51	Changes of the hepatic proteome in murine models for toxically induced fibrogenesis and sclerosing cholangitis. <i>Proteomics</i> , 2006, 6, 6538-6548.	2.2	42
52	Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. <i>FASEB Journal</i> , 2006, 20, 444-454.	0.5	128